Tenaya Therapeutics struck a research collaboration with Alnylam Pharmaceuticals to identify up to 15 genetic targets for cardiovascular disease discovery, with $10 million upfront and potential payments topping $1.13 billion if milestones are met. The partnership combines Tenaya’s genomic target platform with Alnylam’s RNAi development and commercialization scale. The deal funds Tenaya’s target discovery work while granting Alnylam rights to develop and commercialize any resulting RNAi therapeutics. Tenaya said the collaboration supports its parallel internal gene therapy programs (TN‑201, TN‑401) while opening a pathway for RNAi approaches directed at newly validated cardiac targets. For the industry, the arrangement signals increased pharma interest in human‑genetics‑driven target discovery for cardiometabolic disease and reflects a broader strategy of pairing discovery scaleups with RNAi or oligonucleotide developers to accelerate modality translation.